{"DataElement":{"publicId":"2199757","version":"2","preferredName":"Anticoagulant Agent Administered Name","preferredDefinition":"the name of the anticoagulant agent administered to the patient.","longName":"ACOAG_ADM_NM","context":"CTEP","contextVersion":"2.31","DataElementConcept":{"publicId":"2014209","version":"1","preferredName":"Anticoagulant Agent Administered","preferredDefinition":"the administration of anticoagulant to the patient.","longName":"ACOAG_ADM","context":"CTEP","contextVersion":"2.31","ObjectClass":{"publicId":"2184079","version":"1","preferredName":"Anticoagulant Agent","preferredDefinition":"A drug that helps prevent blood clots from forming. Also called a blood thinner.","longName":"Anticoagulant Agent","context":"TEST","contextVersion":"1","Concepts":[{"longName":"Anticoagulant Agent","conceptCode":"C263","definition":"Any agent capable of preventing blood clot formation.","evsSource":"NCI_CONCEPT_CODE","primaryIndicator":"Yes","displayOrder":"0"}],"origin":"NCI Thesaurus","workflowStatus":"RELEASED","registrationStatus":"Application","id":"DB67BCB3-50E0-6E9A-E034-0003BA12F5E7","latestVersionIndicator":"Yes","beginDate":"2004-05-27","endDate":null,"createdBy":"BMCCURRY","dateCreated":"2004-05-27","modifiedBy":"SBR","dateModified":"2005-03-29","changeDescription":null,"administrativeNotes":null,"unresolvedIssues":null,"deletedIndicator":"No"},"Property":{"publicId":"2177665","version":"1","preferredName":"Administered","preferredDefinition":"Given.","longName":"Administered","context":"CTEP","contextVersion":"2.31","Concepts":[{"longName":"Administered","conceptCode":"C25382","definition":"The act of having given something (e.g., a medication or test).","evsSource":"NCI_CONCEPT_CODE","primaryIndicator":"Yes","displayOrder":"0"}],"origin":"NCI Thesaurus","workflowStatus":"RELEASED","registrationStatus":"Application","id":"AE29A78C-516D-3A05-E034-0003BA12F5E7","latestVersionIndicator":"Yes","beginDate":"2002-10-29","endDate":null,"createdBy":"SBREXT","dateCreated":"2002-10-29","modifiedBy":"SBR","dateModified":"2005-03-29","changeDescription":null,"administrativeNotes":null,"unresolvedIssues":null,"deletedIndicator":"No"},"ConceptualDomain":{"publicId":"2008538","version":"1","preferredName":"Therapies","preferredDefinition":"actions or administration of therapeutic agents to produce an effect that is intended to alter the course of a pathologic process (NCI).","longName":"TX","context":"CTEP","contextVersion":"2.31","origin":null,"workflowStatus":"RELEASED","registrationStatus":"Application","id":"B214D04D-9F05-1CA5-E034-0003BA12F5E7","latestVersionIndicator":"Yes","beginDate":"2002-12-18","endDate":null,"createdBy":"MSUPLEY","dateCreated":"2002-12-18","modifiedBy":"SBR","dateModified":"2003-10-29","changeDescription":null,"administrativeNotes":null,"unresolvedIssues":null,"deletedIndicator":"No"},"origin":null,"workflowStatus":"RELEASED","registrationStatus":"Application","id":"B67A9228-B532-053B-E034-0003BA12F5E7","latestVersionIndicator":"Yes","beginDate":"2003-02-12","endDate":null,"createdBy":"CVALMONT","dateCreated":"2003-02-12","modifiedBy":"SBR","dateModified":"2016-06-06","changeDescription":"ISO 11179 compliance.","administrativeNotes":null,"unresolvedIssues":null,"deletedIndicator":"No"},"ValueDomain":{"publicId":"2199756","version":"2","preferredName":"Anticoagulant Agent Administered Name","preferredDefinition":"the name of the administered anticoagulant agent.","longName":"ACOAG_ADM_NM","context":"CTEP","contextVersion":"2.31","type":"Enumerated","dataType":"CHARACTER","minLength":null,"maxLength":"60","minValue":null,"maxValue":null,"decimalPlace":null,"PermissibleValues":[{"value":"Low molecular weight heparin","valueDescription":"Low molecular weight heparin","ValueMeaning":{"publicId":"2573140","version":"1","preferredName":"Low molecular weight heparin","longName":"2573140","preferredDefinition":"Low molecular weight heparin","context":"NCIP","contextVersion":"1","Concepts":[],"origin":null,"workflowStatus":"RELEASED","registrationStatus":"Application","id":"2509CE87-EAC1-5C23-E044-0003BA3F9857","latestVersionIndicator":"Yes","beginDate":"2005-02-09","endDate":null,"createdBy":"CAMPBELB","dateCreated":"2005-02-09","modifiedBy":"CAMPBELB","dateModified":"2005-02-09","changeDescription":null,"administrativeNotes":null,"unresolvedIssues":null,"deletedIndicator":"No"},"origin":null,"id":"E4A38FF1-343F-183D-E040-BB89AD437640","beginDate":"2005-02-09","endDate":null,"createdBy":"CAMPBELB","dateCreated":"2013-08-23","modifiedBy":"ONEDATA","dateModified":"2013-08-23","deletedIndicator":"No"},{"value":"Warfarin","valueDescription":"Warfarin","ValueMeaning":{"publicId":"2573141","version":"1","preferredName":"Warfarin","longName":"2573141v1.00","preferredDefinition":"A synthetic anticoagulant. Warfarin inhibits the regeneration of vitamin K1 epoxide and so the synthesis of vitamin K dependent clotting factors, which include Factors II, VII, IX and X, and the anticoagulant proteins C and S. This inhibition results in a sequential depression of Factors VII, IX, X and II activities. Vitamin K is an essential cofactor for the post ribosomal synthesis of the vitamin K dependent clotting factors. The vitamin promotes the biosynthesis of gamma-carboxyglutamic acid residues in these proteins which are essential for biological activity.","context":"NCIP","contextVersion":"1","Concepts":[{"longName":"Warfarin","conceptCode":"C945","definition":"A synthetic anticoagulant. Warfarin inhibits the regeneration of vitamin K1 epoxide and so the synthesis of vitamin K dependent clotting factors, which include Factors II, VII, IX and X, and the anticoagulant proteins C and S. This inhibition results in a sequential depression of Factors VII, IX, X and II activities. Vitamin K is an essential cofactor for the post ribosomal synthesis of the vitamin K dependent clotting factors. The vitamin promotes the biosynthesis of gamma-carboxyglutamic acid residues in these proteins which are essential for biological activity.","evsSource":"NCI_CONCEPT_CODE","primaryIndicator":"Yes","displayOrder":"0"}],"origin":null,"workflowStatus":"RELEASED","registrationStatus":"Application","id":"2509CE87-EAC2-5C23-E044-0003BA3F9857","latestVersionIndicator":"Yes","beginDate":"2005-02-09","endDate":null,"createdBy":"CAMPBELB","dateCreated":"2005-02-09","modifiedBy":"CLOHNES","dateModified":"2023-08-04","changeDescription":null,"administrativeNotes":"8/4/23 Added missing concepts per cleanup activities cjl.","unresolvedIssues":null,"deletedIndicator":"No"},"origin":null,"id":"E4A38FF1-3449-183D-E040-BB89AD437640","beginDate":"2005-02-09","endDate":null,"createdBy":"CAMPBELB","dateCreated":"2013-08-23","modifiedBy":"ONEDATA","dateModified":"2013-08-23","deletedIndicator":"No"},{"value":"Other","valueDescription":"Other","ValueMeaning":{"publicId":"2567790","version":"1","preferredName":"Other","longName":"2567790","preferredDefinition":"Different than the one(s) previously specified or mentioned.","context":"NCIP","contextVersion":"1","Concepts":[{"longName":"Other","conceptCode":"C17649","definition":"Different than the one(s) previously specified or mentioned.","evsSource":"NCI_CONCEPT_CODE","primaryIndicator":"Yes","displayOrder":"0"}],"origin":null,"workflowStatus":"RELEASED","registrationStatus":"Application","id":"2509CE87-D5DB-5C23-E044-0003BA3F9857","latestVersionIndicator":"Yes","beginDate":"2003-12-31","endDate":null,"createdBy":"SBREXT","dateCreated":"2003-12-31","modifiedBy":"KUMMEROA","dateModified":"2023-11-27","changeDescription":null,"administrativeNotes":null,"unresolvedIssues":null,"deletedIndicator":"No"},"origin":null,"id":"E4A38FF1-3453-183D-E040-BB89AD437640","beginDate":"2003-12-31","endDate":null,"createdBy":"CAMPBELB","dateCreated":"2013-08-23","modifiedBy":"ONEDATA","dateModified":"2013-08-23","deletedIndicator":"No"},{"value":"Acid-Citrate-Dextrose","valueDescription":"Acid-Citrate-Dextrose","ValueMeaning":{"publicId":"2739612","version":"1","preferredName":"Acid-Citrate-Dextrose","longName":"2739612","preferredDefinition":"A citrate anticoagulant used for the collection and preservation of whole blood.","context":"NCIP","contextVersion":"1","Concepts":[{"longName":"Acid-Citrate-Dextrose","conceptCode":"C63375","definition":"A solution of citric acid, sodium citrate, and dextrose used as an anticoagulant in the collection and preservation of whole blood.","evsSource":"NCI_CONCEPT_CODE","primaryIndicator":"Yes","displayOrder":"0"}],"origin":null,"workflowStatus":"RELEASED","registrationStatus":"Application","id":"4A894181-3DFD-24CB-E044-0003BA3F9857","latestVersionIndicator":"Yes","beginDate":null,"endDate":null,"createdBy":"ZHANGW","dateCreated":"2008-04-10","modifiedBy":"SBR","dateModified":"2018-01-19","changeDescription":null,"administrativeNotes":null,"unresolvedIssues":null,"deletedIndicator":"No"},"origin":null,"id":"E4A38FF1-346E-183D-E040-BB89AD437640","beginDate":"2013-08-23","endDate":null,"createdBy":"CAMPBELB","dateCreated":"2013-08-23","modifiedBy":"ONEDATA","dateModified":"2013-08-23","deletedIndicator":"No"},{"value":"Citrate Phosphate Dextrose","valueDescription":"Citrate Phosphate Dextrose","ValueMeaning":{"publicId":"2747083","version":"1","preferredName":"Citrate Phosphate Dextrose","longName":"2747083","preferredDefinition":"A solution of citric acid, sodium citrate, monobasic  sodium phosphate, and dextrose in water used as an anticoagulant in the  collection and preservation of whole blood.","context":"NCIP","contextVersion":"1","Concepts":[{"longName":"Citrate Phosphate Dextrose","conceptCode":"C71605","definition":"A solution of citric acid, sodium citrate, monobasic sodium phosphate, and dextrose in water used as an anticoagulant in the collection and preservation of whole blood.","evsSource":"NCI_CONCEPT_CODE","primaryIndicator":"Yes","displayOrder":"0"}],"origin":null,"workflowStatus":"RELEASED","registrationStatus":"Application","id":"4C926488-BE3F-129F-E044-0003BA3F9857","latestVersionIndicator":"Yes","beginDate":null,"endDate":null,"createdBy":"ZHANGW","dateCreated":"2008-05-06","modifiedBy":"SBR","dateModified":"2018-01-19","changeDescription":null,"administrativeNotes":null,"unresolvedIssues":null,"deletedIndicator":"No"},"origin":null,"id":"E4A38FF1-3482-183D-E040-BB89AD437640","beginDate":"2013-08-23","endDate":null,"createdBy":"CAMPBELB","dateCreated":"2013-08-23","modifiedBy":"ONEDATA","dateModified":"2013-08-23","deletedIndicator":"No"},{"value":"Heparin","valueDescription":"Heparin","ValueMeaning":{"publicId":"2567254","version":"1","preferredName":"Heparin","longName":"2567254","preferredDefinition":"A sulfur-rich glycosaminoglycan with anticoagulant property. Heparin binds to antithrombin III to form a heparin-antithrombin III complex. The complex binds to and irreversibly inactivates thrombin and other activated clotting factors, such as factors IX, X, XI, and XII, thereby preventing the polymerization of fibrinogen to fibrin and the subsequent formation of clots.","context":"NCIP","contextVersion":"1","Concepts":[{"longName":"Heparin","conceptCode":"C539","definition":"A sulfur-rich glycosaminoglycan with anticoagulant property. Heparin binds to antithrombin III to form a heparin-antithrombin III complex. The complex binds to and irreversibly inactivates thrombin and other activated clotting factors, such as factors IX, X, XI, and XII, thereby preventing the polymerization of fibrinogen to fibrin and the subsequent formation of clots.","evsSource":"NCI_CONCEPT_CODE","primaryIndicator":"Yes","displayOrder":"0"}],"origin":null,"workflowStatus":"RELEASED","registrationStatus":"Application","id":"2509CE87-D3C3-5C23-E044-0003BA3F9857","latestVersionIndicator":"Yes","beginDate":"2003-11-14","endDate":null,"createdBy":"SBREXT","dateCreated":"2003-11-14","modifiedBy":"CURTIST","dateModified":"2011-04-12","changeDescription":null,"administrativeNotes":null,"unresolvedIssues":null,"deletedIndicator":"No"},"origin":null,"id":"E4A38FF1-348C-183D-E040-BB89AD437640","beginDate":"2013-08-23","endDate":null,"createdBy":"CAMPBELB","dateCreated":"2013-08-23","modifiedBy":"ONEDATA","dateModified":"2013-08-23","deletedIndicator":"No"},{"value":"Ethylenediaminetetraacetic acid (EDTA)","valueDescription":"Edetic Acid","ValueMeaning":{"publicId":"3210682","version":"1","preferredName":"Edetic Acid","longName":"3210682","preferredDefinition":"The acid form of edetate, a chelating agent with anti-hypercalcemic and anticoagulant properties. Edetic acid binds calcium and heavy metal ions, forming soluble stable complexes which are readily excreted by the kidneys. This results in a decrease in serum calcium levels. This agent is also used as an anticoagulant for blood specimens and is applied as a treatment of lead poisoning.","context":"NCIP","contextVersion":"1","Concepts":[{"longName":"Edetic Acid","conceptCode":"C61742","definition":"The acid form of edetate, a chelating agent with anti-hypercalcemic and anticoagulant properties. Edetic acid binds calcium and heavy metal ions, forming soluble stable complexes which are readily excreted by the kidneys. This results in a decrease in serum calcium levels. This agent is also used as an anticoagulant for blood specimens and is applied as a treatment of lead poisoning.","evsSource":"NCI_CONCEPT_CODE","primaryIndicator":"Yes","displayOrder":"0"}],"origin":null,"workflowStatus":"RELEASED","registrationStatus":"Application","id":"9F52E0A8-E413-4837-E040-BB89AD437666","latestVersionIndicator":"Yes","beginDate":"2011-03-25","endDate":null,"createdBy":"UMLLOADER_CBM","dateCreated":"2011-03-25","modifiedBy":"KUMMEROA","dateModified":"2023-03-13","changeDescription":null,"administrativeNotes":"2023.3.13 Alt VM added per ticket request CADSR0002119. ak","unresolvedIssues":null,"deletedIndicator":"No"},"origin":null,"id":"83EA06E9-52E8-1690-E053-F662850A3A68","beginDate":"2019-03-12","endDate":null,"createdBy":"CAMPBELB","dateCreated":"2019-03-12","modifiedBy":"ONEDATA","dateModified":"2019-03-12","deletedIndicator":"No"}],"ConceptualDomain":{"publicId":"2008538","version":"1","preferredName":"Therapies","preferredDefinition":"actions or administration of therapeutic agents to produce an effect that is intended to alter the course of a pathologic process (NCI).","longName":"TX","context":"CTEP","contextVersion":"2.31","origin":null,"workflowStatus":"RELEASED","registrationStatus":"Application","id":"B214D04D-9F05-1CA5-E034-0003BA12F5E7","latestVersionIndicator":"Yes","beginDate":"2002-12-18","endDate":null,"createdBy":"MSUPLEY","dateCreated":"2002-12-18","modifiedBy":"SBR","dateModified":"2003-10-29","changeDescription":null,"administrativeNotes":null,"unresolvedIssues":null,"deletedIndicator":"No"},"RepresentationTerm":{"publicId":"2229718","version":"1","preferredName":"Name","preferredDefinition":"The words or language units by which a thing is known.","longName":"C42614","context":"NCIP","contextVersion":"1","Concepts":[{"longName":"Name","conceptCode":"C42614","definition":"The words or language units by which a thing is known.","evsSource":"NCI_CONCEPT_CODE","primaryIndicator":"Yes","displayOrder":"0"}],"origin":"NCI Thesaurus","workflowStatus":"RELEASED","registrationStatus":"Standard","id":"F6EF4E2B-76AE-72C1-E034-0003BA3F9857","latestVersionIndicator":"Yes","beginDate":"2005-05-16","endDate":null,"createdBy":"MAESKEB","dateCreated":"2005-05-16","modifiedBy":"ONEDATA","dateModified":"2005-05-16","changeDescription":null,"administrativeNotes":null,"unresolvedIssues":null,"deletedIndicator":"No"},"origin":"CALGB CRF:Cancer and Leukemia Group B Case Report Form","workflowStatus":"RELEASED","registrationStatus":"Application","id":"E4A38FF1-3429-183D-E040-BB89AD437640","latestVersionIndicator":"Yes","beginDate":"2013-08-23","endDate":null,"createdBy":"CAMPBELB","dateCreated":"2013-08-23","modifiedBy":"CAMPBELB","dateModified":"2019-03-12","changeDescription":"Revised Rep Term and increased Max Length.","administrativeNotes":null,"unresolvedIssues":null,"deletedIndicator":"No"},"ClassificationSchemes":[{"publicId":"2008587","version":"2","longName":"Type of Disease","context":"CTEP","ClassificationSchemeItems":[{"publicId":"2811911","version":"1","longName":"Upper GI","context":"CTEP"}]},{"publicId":"2008589","version":"2","longName":"Type of Category","context":"CTEP","ClassificationSchemeItems":[{"publicId":"2811963","version":"1","longName":"Treatment","context":"CTEP"}]}],"AlternateNames":[{"name":"NHLBI","type":"USED_BY","context":"NHLBI"}],"ReferenceDocuments":[{"name":"Agent code","type":"Preferred Question Text","description":"Agent code","url":null,"context":"CTEP"},{"name":"Specify anticoagulant:","type":"Alternate Question Text","description":"Specify anticoagulant:","url":null,"context":"NHLBI"},{"name":"Specify anticoagulant(s)","type":"Alternate Question Text","description":"Specify anticoagulant(s)","url":null,"context":"NHLBI"}],"origin":"CALGB CRF:Cancer and Leukemia Group B Case Report Form","workflowStatus":"RELEASED","registrationStatus":"Qualified","id":"E4A38FF1-349C-183D-E040-BB89AD437640","latestVersionIndicator":"Yes","beginDate":"2013-08-23","endDate":null,"createdBy":"CAMPBELB","dateCreated":"2013-08-23","modifiedBy":"KUMMEROA","dateModified":"2019-03-12","changeDescription":"Increased max length for VD and change rep term.","administrativeNotes":null,"unresolvedIssues":null,"deletedIndicator":"No"}}